![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Thursday, October 15, 2015 9:27:05 AM
Bristol-Myers Squibb (BMY) goes all in with Five Prime Therapeutics (FPRX) in a license and collaboration deal worth up to $1.74B. The partnership will focus on the development of Five Prime's colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008, in combination with Opdivo (nivolumab) and other therapies.
The new agreement replaces the companies' existing collaboration to evaluate Opdivo with FPA008 in six tumor types.Under the terms of the agreement, Five Prime will receive an upfront payment of $350M, up to $1.05B in development and regulatory milestones for CSF1R oncology indications (including combinations with Opdivo and any other agent), up to $340M in development and regulatory milestones for CSF1R non-oncology indications and double-digit royalties on commercial sales (higher if Five Prime elects to co-promote in the U.S.).
DUKE BASKETBALL and NOTRE DAME FOOTBALL
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM